Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding

Background and study aims A new hemostatic adhesive powder (UI-EWD) was developed to reduce high rebleeding rates and technical challenges associated with application of currently available hemostatic powders. The aim of the current study was to assess performance of UI-EWD for nonvariceal upper gas...

Full description

Bibliographic Details
Main Authors: Jin-Seok Park, Hyung Kil Kim, Yong Woon Shin, Kye Sook Kwon, Don Haeng Lee
Format: Article
Language:English
Published: Georg Thieme Verlag KG 2019-12-01
Series:Endoscopy International Open
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/a-0982-3194
_version_ 1818187485363044352
author Jin-Seok Park
Hyung Kil Kim
Yong Woon Shin
Kye Sook Kwon
Don Haeng Lee
author_facet Jin-Seok Park
Hyung Kil Kim
Yong Woon Shin
Kye Sook Kwon
Don Haeng Lee
author_sort Jin-Seok Park
collection DOAJ
description Background and study aims A new hemostatic adhesive powder (UI-EWD) was developed to reduce high rebleeding rates and technical challenges associated with application of currently available hemostatic powders. The aim of the current study was to assess performance of UI-EWD for nonvariceal upper gastrointestinal bleeding (NVUGIB). Patients and methods A total of 56 consecutive patients that received UI-EWD monotherapy for endoscopic hemostasis due to NVUGIB were retrospectively reviewed. Main study outcomes were success rates with immediate hemostasis and rebleeding within 30 days. Outcomes were analyzed by reviewing patient medical records. Results Etiologies of bleeding were: post-endoscopic therapy bleeding in 46 (82.1 %), peptic ulcer in 8 (14.3 %), tumor in 1 (1.8 %), and other in 1 (1.8 %). UI-EWD was successfully applied at bleeding site in all cases. The success rate of immediate hemostasis was 96.4 % (54/56), and the 30-day rebleeding rate among patients that achieved immediate hemostasis was 3.7 % (2/54). No adverse event related to use of UI-EWD occurred. Conclusion UI-EWD was found to have a high immediate hemostasis success rate in NVUGIB when used as monotherapy and showed promising results in terms of preventing rebleeding.
first_indexed 2024-12-11T23:11:47Z
format Article
id doaj.art-6344774ea4fe49bca1392eb275dee346
institution Directory Open Access Journal
issn 2364-3722
2196-9736
language English
last_indexed 2024-12-11T23:11:47Z
publishDate 2019-12-01
publisher Georg Thieme Verlag KG
record_format Article
series Endoscopy International Open
spelling doaj.art-6344774ea4fe49bca1392eb275dee3462022-12-22T00:46:41ZengGeorg Thieme Verlag KGEndoscopy International Open2364-37222196-97362019-12-010712E1763E176710.1055/a-0982-3194Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleedingJin-Seok Park0Hyung Kil Kim1Yong Woon Shin2Kye Sook Kwon3Don Haeng Lee4Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea Background and study aims A new hemostatic adhesive powder (UI-EWD) was developed to reduce high rebleeding rates and technical challenges associated with application of currently available hemostatic powders. The aim of the current study was to assess performance of UI-EWD for nonvariceal upper gastrointestinal bleeding (NVUGIB). Patients and methods A total of 56 consecutive patients that received UI-EWD monotherapy for endoscopic hemostasis due to NVUGIB were retrospectively reviewed. Main study outcomes were success rates with immediate hemostasis and rebleeding within 30 days. Outcomes were analyzed by reviewing patient medical records. Results Etiologies of bleeding were: post-endoscopic therapy bleeding in 46 (82.1 %), peptic ulcer in 8 (14.3 %), tumor in 1 (1.8 %), and other in 1 (1.8 %). UI-EWD was successfully applied at bleeding site in all cases. The success rate of immediate hemostasis was 96.4 % (54/56), and the 30-day rebleeding rate among patients that achieved immediate hemostasis was 3.7 % (2/54). No adverse event related to use of UI-EWD occurred. Conclusion UI-EWD was found to have a high immediate hemostasis success rate in NVUGIB when used as monotherapy and showed promising results in terms of preventing rebleeding.http://www.thieme-connect.de/DOI/DOI?10.1055/a-0982-3194
spellingShingle Jin-Seok Park
Hyung Kil Kim
Yong Woon Shin
Kye Sook Kwon
Don Haeng Lee
Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding
Endoscopy International Open
title Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding
title_full Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding
title_fullStr Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding
title_full_unstemmed Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding
title_short Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding
title_sort novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding
url http://www.thieme-connect.de/DOI/DOI?10.1055/a-0982-3194
work_keys_str_mv AT jinseokpark novelhemostaticadhesivepowderfornonvaricealuppergastrointestinalbleeding
AT hyungkilkim novelhemostaticadhesivepowderfornonvaricealuppergastrointestinalbleeding
AT yongwoonshin novelhemostaticadhesivepowderfornonvaricealuppergastrointestinalbleeding
AT kyesookkwon novelhemostaticadhesivepowderfornonvaricealuppergastrointestinalbleeding
AT donhaenglee novelhemostaticadhesivepowderfornonvaricealuppergastrointestinalbleeding